Oxaliplatin has long been a frontline weapon in combating colorectal cancer and various other malignancies. Despite its efficacy, resistance to oxaliplatin remains a formidable barrier, often leading to treatment failure and disease progression. Understanding the molecular underpinnings of this resistance is paramount for improving clinical outcomes. Tajik and Ghafouri-Fard’s investigation delineates how circRNAs intricately regulate cellular pathways that govern oxaliplatin sensitivity, charting new territories in cancer therapeutics.

CircRNAs are distinctive in their covalently closed loop structures, which confer exceptional stability compared to linear RNAs. This unique topology protects them from exonuclease-mediated degradation, allowing them to accumulate and exert sustained regulatory effects. The researchers delve into how this stability enables circRNAs to sponge microRNAs (miRNAs), interact with RNA binding proteins, and modulate transcriptional and post-transcriptional landscapes, ultimately influencing how cancer cells respond to chemotherapy.

One of the pivotal revelations from the study lies in the identification of specific circRNAs that act as molecular switches toggling oxaliplatin resistance. These circRNAs function predominantly as competing endogenous RNAs (ceRNAs) by sequestering miRNAs that would otherwise inhibit key oncogenes or drug resistance-associated genes. For instance, the circRNA-mediated sponging of tumor-suppressive miRNAs can alleviate repression on DNA repair genes, thus facilitating cancer cell survival during oxaliplatin-induced DNA damage.

Furthermore, the authors illuminate the bidirectional relationship between circRNAs and signaling pathways implicated in drug resistance. CircRNAs have been shown to modulate pathways such as Wnt/β-catenin, PI3K/Akt, and NF-κB, which confer survival advantages and attenuate apoptotic responses under chemotherapeutic stress. By fine-tuning these signaling cascades, circRNAs sculpt cellular landscapes that favor resistance phenotypes.

Importantly, the study underscores that circRNAs are not mere bystanders but active participants in the epigenetic remodeling that accompanies oxaliplatin resistance. They contribute to the reprogramming of chromatin states and transcriptional machinery through interactions with chromatin modifiers and transcription factors, thereby promoting gene expression patterns that support drug tolerance.

The therapeutic implications are profound. Targeting circRNAs or their interaction networks could restore oxaliplatin sensitivity and circumvent resistance. The study discusses innovative strategies like antisense oligonucleotides (ASOs) and CRISPR/Cas-mediated approaches that selectively degrade or alter circRNAs, offering precision intervention points. Additionally, circRNAs themselves may serve as prognostic biomarkers to predict patient responsiveness to oxaliplatin-based treatment regimens, enabling personalized medicine.

Intriguingly, circRNAs also modulate immune responses within the tumor microenvironment, which can indirectly influence chemotherapy efficacy. By regulating immune checkpoints and cytokine milieus, circRNAs may dictate the balance between immune surveillance and evasion, thus intersecting with immunotherapeutic strategies.

This research opens new avenues for combinatorial therapies. By integrating circRNA-targeting modalities with conventional oxaliplatin chemotherapy or emerging immunotherapies, clinicians may surmount resistance barriers, leading to more durable remissions. The exploitation of circRNA pathways offers a dual advantage: enhancing drug efficacy while minimizing off-target toxicities through specific molecular targeting.

Nevertheless, challenges persist in translating these molecular insights into clinical practice. The complexity of circRNA expression profiles across tumor types, heterogeneity among patients, and the dynamic nature of RNA interactions necessitate comprehensive profiling and longitudinal studies. Moreover, efficient delivery systems for circRNA-targeted therapeutics remain a crucial area for technological advancement.

Despite these hurdles, the revelation of circRNAs as master regulators of oxaliplatin response embodies a paradigm shift. It underscores the necessity of exploring non-coding RNA territories to unravel resistance mechanisms that have remained elusive for decades. The fundamental knowledge garnered not only deepens our understanding of cancer biology but also propels the development of next-generation therapeutics with the potential to redefine cancer treatment landscapes.

From a broader perspective, the study exemplifies the evolving narrative of precision oncology, where molecular intricacies guide tailored treatment decisions. CircRNAs offer a tantalizing glimpse into the molecular dark matter of the genome, turning what was once considered “junk” RNA into a treasure trove of therapeutic targets.

Future investigations will likely focus on expanding the catalog of circRNAs involved in drug resistance, unraveling their tissue-specific roles, and elucidating their interactions within larger regulatory networks. High-throughput sequencing combined with sophisticated bioinformatics will accelerate discoveries, while functional validation in preclinical models will pave the way for clinical translation.

In conclusion, Tajik and Ghafouri-Fard’s seminal work affirms the critical regulatory capacity of circRNAs in oxaliplatin response and resistance, positioning these non-coding RNAs at the forefront of cancer research and therapy innovation. As the fight against chemoresistant cancers intensifies, circRNAs stand out as promising allies, offering hope for more effective, personalized, and durable treatment outcomes.

Subject of Research: Circular RNAs as regulators of oxaliplatin response and resistance in cancer therapy

Article Title: Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy

Article References:

Tajik, Z., Ghafouri-Fard, S. Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.
Med Oncol 43, 38 (2026). https://doi.org/10.1007/s12032-025-03171-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03171-9

The study focused on HCT116 cells, a well-established human colorectal cancer cell line widely used in cancer research. By comparing regular HCT116 cells with their 5-FU-resistant counterparts, the researchers conducted a comprehensive analysis integrating whole-genome sequencing and transcriptome profiling. This dual approach allowed them to uncover mutations, gene expression shifts, and pathway alterations that collectively confer enhanced aggressiveness to resistant cells.

Chemotherapy resistance is not simply a matter of one or two gene mutations but involves a multifaceted rewiring of cellular networks. The researchers identified significant genetic alterations across key oncogenes and tumor suppressor genes within 5-FU-resistant HCT116 cells. Notably, mutations were detected in genes that regulate DNA repair mechanisms, apoptosis, and cell cycle control. These changes contribute to the cells’ ability to evade drug-induced damage and sustain uncontrolled proliferation despite therapeutic pressure.

Simultaneously, transcriptomic profiling revealed dramatic shifts in gene expression patterns, indicating that the resistant cells undergo profound phenotypic changes at the RNA level. Genes involved in epithelial-to-mesenchymal transition (EMT), a process linked to metastasis and invasion, were upregulated. This transition endows cancer cells with enhanced motility and invasive capabilities. The data pinpointed key EMT markers elevated in resistant cells, correlating with their heightened aggressiveness observed in functional assays.

Beyond EMT, transcriptomic data showed dysregulation of multiple signaling pathways implicated in survival and drug resistance, such as the PI3K/AKT/mTOR axis and Wnt/β-catenin pathway. Such pathways are notorious for driving cancer progression and promoting a stem-like state in tumor cells, which may underlie the notorious difficulty in eradicating chemotherapy-resistant cancer populations. The amplified activity of these pathways could represent vulnerabilities for therapeutic exploitation.

Furthermore, the study shed light on changes in the tumor microenvironment modulation by resistant cells. Genes coding for secreted factors, cytokines, and extracellular matrix components were differentially expressed, suggesting that resistant cells may remodel their surroundings to create a more permissive niche for growth and dissemination. This microenvironmental conditioning could further exacerbate disease aggressiveness and resistance to treatment.

The researchers also explored metabolic adaptations, noting that resistant HCT116 cells reprogram their metabolism to sustain survival under chemotherapeutic stress. Upregulation of glycolytic enzymes and alterations in mitochondrial function were observed, aligning with a metabolic shift that supports rapid proliferation and resilience in the face of 5-FU toxicity. These findings align with the growing recognition that metabolic plasticity is a hallmark of aggressive cancer phenotypes.

Importantly, the integration of genetic and transcriptomic data enabled the identification of candidate biomarkers that could predict resistance and disease progression. Such markers not only have prognostic potential but may guide the development of combination therapies designed to prevent or overcome chemoresistance. This could mark a significant leap toward personalized treatment strategies improving patient outcomes.

The use of cutting-edge sequencing technologies paired with robust bioinformatics pipelines highlights the power of multi-omics approaches in unraveling the complexity of cancer biology. By dissecting both the static genetic blueprint and dynamic gene expression changes, this study provides a holistic view of resistance mechanisms that single-layer analyses might miss.

Given the global burden of colorectal cancer, particularly due to its high incidence and mortality rates associated with chemoresistant disease, these insights are timely and crucial. Understanding the molecular underpinnings of resistance can inform the design of next-generation therapeutics and clinical trials aimed at enhancing the efficacy of existing chemotherapy regimens.

While the study’s focus on in vitro cell lines may raise questions about translational relevance, the findings lay essential groundwork for further validation in animal models and patient-derived samples. Future research will need to confirm whether the identified alterations consistently appear in clinical resistant tumors and contribute causally to therapy failure.

The detailed characterization of 5-FU-resistant HCT116 cells also underscores the heterogeneity of colorectal cancer and the necessity to tailor treatments to evolving tumor landscapes. Resistance emerges not from a singular cause but from a confluence of genetic, transcriptomic, and metabolic shifts—each offering a therapeutic target.

In conclusion, this research advances our understanding of how colorectal cancer cells adapt and thrive despite 5-FU chemotherapy. By revealing the genetic and transcriptomic changes underlying enhanced aggressiveness in resistant cells, the study paves the way for innovative interventions aimed at dismantling the defenses of drug-resistant cancer. As researchers worldwide build upon these findings, hope grows for more effective strategies to combat the formidable challenge of chemotherapy resistance in colorectal cancer.

Subject of Research: Genetic and transcriptomic changes in 5-fluorouracil-resistant colorectal cancer cells.

Article Title: Genetic and transcriptomic alterations underlying aggressiveness in 5-fluorouracil-resistant HCT116 cells.

Article References:
Sooksaen, P., Thim-uam, A., Praphasawat, R. et al. Genetic and transcriptomic alterations underlying aggressiveness in 5-fluorouracil-resistant HCT116 cells. Med Oncol 42, 512 (2025). https://doi.org/10.1007/s12032-025-03078-5

Image Credits: AI Generated